The combination therapy of BRD4 inhibitor (JQ1) plus MEK inhibitor (PD901) synergistically downregulated the transcription factor 19 (TCF19), increased apoptosis in vivo, reduced the growth of NRAS‐mutant melanoma, and prolonged the survival of mice which resisted to MAPK inhibitors and ICIs [295]. Here, TCF19 is linked to melanoma.